Filing Flows › Health Care › ClearPoint Neuro (CLPT)
ClearPoint Neuro (CLPT) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Oct 28, 2026 · ClearPoint Neuro (CLPT) Q3 2026 earnings results →
Q3 2026 Revenue up 36% year over year to $12.1M · 62¢ of every $1 of revenue lost · operating margin -52.4%
ClearPoint Neuro made $12.1M in Q3 2026 (+36% Y/Y): Product $7.9M, Capital Equipment and Software $1.7M, Capital Equipment and Software Systems and Software Products $1.3M. Operating margin -52.4%, net loss $7.5M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Oct 28, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $12.1M in Q3 2026, up 36% year over year and up 11% from the previous quarter. Service was the largest line at 35% of revenue. Capital Equipment and Software added $705K year over year (up 68%), 22% of the total change. Biologics and Drug Delivery Disposable Products declined 8%.
Gross margin was 58.5%, down 4.7 points from Q3 2025. Operating costs exceeded revenue by $6.3M, an operating margin of -52.4%. Operating expenses grew 23% against revenue growth of 36%. The fastest-growing cost line was Other operating costs (+44%). The quarter ended with a net loss of $7.5M, narrower than the previous quarter's $11.3M loss.
Operating cash flow was −$5.1M. Non-cash charges added back $103K of depreciation and amortization and $1.9M of share-based compensation. Working capital and other items added $365K. Capital expenditures of $137K exceeded it, leaving free cash flow of −$5.2M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Oct 28, 2026 | $12.1M | +36% | -52.4% | −$7.5M | −$5.1M |
| Q2 2026 | 10-Q | Aug 3, 2026 | $10.9M | +18% | -94.2% | −$11.3M | −$7.0M |
| Q1 2026 | 10-Q | May 13, 2026 | $12.1M | +43% | -69.9% | −$9.6M | −$8.0M |
| Q4 2025 | 10-K | Mar 17, 2026 | $10.4M | +34% | -67.7% | −$7.8M | −$12.1M |
| Q3 2025 | 10-Q | Nov 6, 2025 | $8.9M | +9% | -59.5% | −$5.9M | −$3.1M |
| Q2 2025 | 10-Q | Aug 12, 2025 | $9.2M | +17% | -61.6% | −$5.8M | −$2.6M |
| Q1 2025 | 10-Q | May 13, 2025 | $8.5M | +11% | -72.6% | −$6.0M | −$6.2M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Sells to
About ClearPoint Neuro
ClearPoint Neuro is a device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company uniquely provides both established clinical products as well as preclinical development services for controlled drug and device delivery. The Company’s flagship product, the ClearPoint Neuro Navigation System, has FDA clearance and is CE-marked. ClearPoint Neuro is engaged with healthcare and research centers in North America, Europe, Asia, and South America. The Company is also partnered with the most innovative pharmaceutical/biotech companies, academic centers, and contract research organizations, providing solutions for direct central nervous system delivery of therapeutics in preclinical studies and clinical trials worldwide.
In its own words, from its 8-K, filed Aug 3, 2026.
ClearPoint Neuro against its Surgical & Medical Instruments & Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +36% against the peers' median +5%. Operating margin: -52.4% against the peers' median 13.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| CLPT ClearPoint Neuro | Q3 2026 | $12.1M | +36% | -52.4% |
| MDLN Medline | Q3 2026 | $7.9B | +10% | 6.4% |
| MMM 3M | Q3 2026 | $6.6B | +1% | 23.7% |
| SYK Stryker | Q3 2026 | $6.5B | +8% | 15.9% |
| BSX Boston Scientific | Q3 2026 | $5.1B | +1% | 16.1% |
| BDX Becton Dickinson | Q3 FY26 | $5.0B | +5% | 13.3% |
| BAX Baxter International | Q3 2026 | $3.0B | +5% | 7.6% |
| SOLV Solventum | Q3 2026 | $1.9B | -7% | 3.5% |
| RMD ResMed | Q1 FY27 | $1.4B | +6% | 32.0% |
Source: ClearPoint Neuro 10-Q on SEC EDGAR · CIK 1285550 · Surgical & Medical Instruments & Apparatus
13F: who owns CLPT and who is buying
More on CLPT
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results